Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kuvan in children under 4 years old with phenylketonuria
2009-015768-33Phase 3Completed
- Sponsor
- BioMarin Pharmaceutical Inc.
- Start
- Oct 2010
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sapropterin in phenylketonuria (PKU) (2 arms), sponsored by BioMarin Pharmaceutical Inc. Primary endpoint: Dietary phenylalanine tolerance at 26 weeks. Started Oct 2010; status: completed.
02
Drugs
sapropterin
03
Conditions
phenylketonuria (PKU)
Beyond the preview
Go deeper on 2009-015768-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015768-33.